Description de l’évolution des délivrances d'antidiabétiques hors Insuline en France de 2014 à 2024 à partir des données de l’Assurance Maladie
Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: Importance: type 2 diabetes is a major and growing public health concern in France, with innovative therapies such as SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RAs) reshaping treatment recommendations. Objective: we aimed to describe the evolution of dispensing of non-insulin antidiabetic drugs in France between 2014 and 2024. Methods: we conducted a retrospective descriptive study based on the Open Medic database from French National Health Insurance, covering annual outpatient drug dispensing in pharmacies that were at least partially reimbursed. All patients who were dispensed at least one non-insulin antidiabetic drug between 2014 and 2024 were included. The primary endpoint of this study was the number of packages of non-insulin antidiabetic drugs dispensed in France between 2014 and 2024. Stratified analyses were conducted according to age group, gender and prescriber specialty. Results: from 2014 to 2024, over 633 million boxes of reimbursed non-insulin antidiabetic drugs were dispensed. Metformin remained the most dispensed treatment during the study period, accounting for 42% of all non-insulin antidiabetic dispensed in 2024. Sulfonylureas declined steadily (from 23% in 2014 to 11% in 2024), while SGLT2i and GLP-1RAs grew sharply after 2019 and surpassed sulfonylureas by 2024, representing 18% and 11% of all non-insulin antidiabetic dispensed, respectively. Endocrinologists were quicker to prescribe these innovative therapies. At initiation, younger patients accounted for a higher proportion than in the subsequent years and compared to other non-insulin antidiabetic drugs. Although dispensed volumes remained relatively stable, total expenditures increased by 66% between 2018 and 2024, with SGLT2i and GLP-1RAs accounting for nearly 80% of antidiabetic drug costs in 2024. Conclusion: over the study period, metformin remained the most frequently dispensed treatment. The introduction of SGLT2i and newer GLP1-RAs was accompanied by a decline in the use of sulfonylureas. Despite relatively stable overall dispensing volumes, expenditures have increased substantially, driven by the higher cost of innovative treatments.
Source: HAL
Author: Bommelaer, Marin
Institution: Université Paris Cité
Language: French
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7170227158